Novel mutations in pyridoxine-dependent epilepsy

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Pyridoxine-dependent epilepsy (PDE) is a rare, autosomal recessive metabolic disorder.
• Neonatal seizures in PDE are often refractory to standard anti-epileptic drugs.
• Early diagnosis and treatment are crucial for improving patient outcomes.

Observation:

• A neonate presented with symptoms consistent with PDE.
• The patient carried two novel mutations in the ALDH7A1 gene: c.[852_856delCTTAG] + [1230C > A]; p.[(Phe410Leu)] + p.[(Leu285CysfsX26)].
• Biomarker measurement allowed for diagnosis without necessitating pyridoxine withdrawal.

Findings:

• Identification of two new ALDH7A1 gene mutations associated with PDE.
• Demonstration that PDE can be diagnosed using biomarkers, bypassing the need for pyridoxine withdrawal.
• Successful treatment of the patient with pyridoxine supplementation.

Implications:

• The identified mutations offer potential for prenatal diagnosis of PDE.
• The proposed diagnostic procedure may streamline early detection of PDE.
• Timely intervention with pyridoxine supplementation supports normal neurological development in affected infants.